RXRX - Recursion Pharmaceuticals, Inc.
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The old healthcare model is breaking down.
Earlier this year, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), which represents a new way of treating this rare genetic condition without immediate surgery.
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 per share a year ago.
SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.41, indicating a -1.45% shift from the previous trading day.
Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company's Board of Directors.
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Recursion Pharmaceuticals, Inc. remains a Hold as competitive risks persist and the company is years away from meaningful pipeline revenue. RXRX's AI-driven Recursion OS platform shows strong potential, but has yet to demonstrate a clear competitive edge or superior scalability versus well-funded peers. Share dilution and accelerating cash burn threaten RXRX shareholder value, with at least 18-24 months before potential pipeline revenue and likely further capital raises.
Recursion Pharmaceuticals (RXRX) reached $3.5 at the closing of the latest trading day, reflecting a -6.17% change compared to its last close.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Recursion Pharmaceuticals (RXRX) closed at $3.6 in the latest trading session, marking a -4% move from the prior day.
Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day.
Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026 Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives.
Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared to its last close.
One of these is not like the other.
Citeline, a leader in clinical solutions for the life sciences, announced an expanded strategic partnership with Recursion, a leading tech-bio company.